---

title: "Long-COVID research just got a big funding boost: will it find new treatments?"
tags:
- üì∞ News
- üíä Treatment
- ‚è≥ Trial
created: '2025-12-08'
published: '2025-12-08'

---


<details>
<summary>Marshall (2025)</summary>

- **Authors:** Michael Marshall.
- **Institutes:** Nature (News Editorial).
- **Publisher:** Nature
- **Link:** [DOI](https://doi.org/10.1038/d41586-025-03904-w)

</details>


## Summary

This report signifies a major turning point in the systemic recognition and funding of ME/CFS and Long COVID. By dedicating half a billion euros over ten years, the German government is creating a stable environment for scientists to search for biological causes rather than just managing symptoms. For patients, this means a higher likelihood of upcoming clinical trials and the potential discovery of objective biomarkers that could eventually lead to a definitive diagnostic blood test. While the road to a "cure" remains long, this level of investment is designed to bridge the gap between basic laboratory science and real-world clinical treatments.

## What was researched?

This news analysis examines the German government‚Äôs decision to commit ‚Ç¨500 million ($582 million) to research post-infectious diseases. It explores whether this massive funding boost will be sufficient to discover effective treatments and diagnostic biomarkers for conditions like Long COVID and ME/CFS.

## Why was it researched?

Post-infectious syndromes have created a global health crisis, with Long COVID estimated to cost the world economy US$1 trillion annually. Despite the high prevalence‚Äîaffecting nearly one in five people in Germany‚Äîthere remains a critical lack of validated therapies and a "black box" regarding the underlying biological mechanisms, prompting the need for a large-scale, coordinated research "moonshot."

## How was it researched?

This was a news investigation and scientific policy analysis. The author synthesized data from recent epidemiological studies in Germany and the US, interviewed leading clinical epidemiologists and researchers (including Ziyad Al-Aly and Rafael Mikolajczyk), and reviewed the strategic framework of Germany's "National Decade Against Post-Infectious Diseases" (2026‚Äì2036).

## What has been found?

The German government has formally launched a 10-year initiative with a ‚Ç¨500 million budget specifically targeting Long COVID, ME/CFS, and other post-viral conditions. The reporting highlights that an expert group has already identified four medications for prioritized off-label use evaluation to manage symptoms. Furthermore, the funding will support the National Clinical Study Group (NKSG) to accelerate clinical trials for promising candidates, such as the aptamer drug BC007 üíä, which is currently being investigated for its potential to improve microcirculation.

## Discussion

The author notes that while ‚Ç¨500 million is a substantial investment, it is not unlimited, as large-scale Phase III clinical trials can cost upwards of $50 million each. There is an ongoing debate within the scientific community and among patient advocates regarding whether the funds will prioritize biomedical research into viral persistence and autoimmunity or be diverted toward less effective biopsychosocial (psychological) models. A key strength identified is the multi-year commitment, which allows for longitudinal studies that are often missing in short-term funding cycles.

## Conclusion & Future Work

The article concludes that the funding represents a "great step in the right direction" and a significant political shift toward recognizing post-infectious diseases as a major public health priority. Future work will involve setting up the research infrastructure for the 2026‚Äì2036 decade, with a focus on standardizing metrics for economic and health impacts and conducting large-scale clinical trials.
